Validity testing of patient objections to acceptance of tamper-resistant opioid formulations

Abstract

As tamper-resistant formulations (TRFs) are introduced in the hope of presenting obstacles to drug abuse, clinicians will need to judge whether a patient objecting to a TRF has legitimate complaints or is seeking a more easily-abused alternative. Experienced pain clinicians from the US Northeast, Midwest, and Northwest regions were asked to recount any objections raised by patients after switching from the old formulation of oxycodone controlled release (CR) to the tamper-resistant formulation of oxycodone CR.